Global Prostaglandin I2 Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Prostaglandin I2 Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Prostaglandin I2 (PGI), or prostacyclin, is one of the prostanoids, a group of local hormones that are best known for their roles in mediating inflammation.
Prostaglandin I2 report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Prostaglandin I2 market is projected to reach US$ 3768.5 million in 2029, increasing from US$ 2457 million in 2022, with the CAGR of 6.3% during the period of 2024 to 2029. Demand from For Injection and For Oral are the major drivers for the industry.
The prostaglandin I2 (PGI2) market is driven by its critical role as a potent vasodilator and inhibitor of platelet aggregation, making it an essential therapeutic option for various cardiovascular conditions. PGI2, also known as prostacyclin, is used to treat pulmonary arterial hypertension (PAH), preventing blood clot formation and improving blood flow in affected patients. The increasing prevalence of PAH and the growing awareness of its therapeutic benefits contribute to market growth. Moreover, advancements in pharmaceutical research and biotechnology have led to the development of new formulations and delivery methods for PGI2, further expanding its application in cardiovascular medicine. However, the market also faces challenges, including the high cost of PGI2 therapy, which may limit patient access and affordability. Additionally, the need for continuous infusion in some cases and potential side effects, such as bleeding complications, can pose obstacles for widespread adoption. To succeed in this market, manufacturers must focus on cost-effectiveness, patient-friendly administration methods, and conducting extensive clinical trials to establish the safety and efficacy of PGI2 therapies for various cardiovascular conditions, ensuring its continued use as a critical treatment option.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Prostaglandin I2 market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
United Therapeutics
J & J
GSK
Teva
Toray
Tide Pharma
Bayer AG
Segment by Type
Epoprostenol Sodium
Treprostinil
Iloprost
Beraprost Sodium
For Injection
For Oral
For Inhalation
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Prostaglandin I2 market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Prostaglandin I2, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Prostaglandin I2 industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Prostaglandin I2 in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Prostaglandin I2 introduction, etc. Prostaglandin I2 Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Prostaglandin I2 market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Prostaglandin I2 report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Prostaglandin I2 market is projected to reach US$ 3768.5 million in 2029, increasing from US$ 2457 million in 2022, with the CAGR of 6.3% during the period of 2024 to 2029. Demand from For Injection and For Oral are the major drivers for the industry.
The prostaglandin I2 (PGI2) market is driven by its critical role as a potent vasodilator and inhibitor of platelet aggregation, making it an essential therapeutic option for various cardiovascular conditions. PGI2, also known as prostacyclin, is used to treat pulmonary arterial hypertension (PAH), preventing blood clot formation and improving blood flow in affected patients. The increasing prevalence of PAH and the growing awareness of its therapeutic benefits contribute to market growth. Moreover, advancements in pharmaceutical research and biotechnology have led to the development of new formulations and delivery methods for PGI2, further expanding its application in cardiovascular medicine. However, the market also faces challenges, including the high cost of PGI2 therapy, which may limit patient access and affordability. Additionally, the need for continuous infusion in some cases and potential side effects, such as bleeding complications, can pose obstacles for widespread adoption. To succeed in this market, manufacturers must focus on cost-effectiveness, patient-friendly administration methods, and conducting extensive clinical trials to establish the safety and efficacy of PGI2 therapies for various cardiovascular conditions, ensuring its continued use as a critical treatment option.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Prostaglandin I2 market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
United Therapeutics
J & J
GSK
Teva
Toray
Tide Pharma
Bayer AG
Segment by Type
Epoprostenol Sodium
Treprostinil
Iloprost
Beraprost Sodium
Segment by Application
For Injection
For Oral
For Inhalation
Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Prostaglandin I2 market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Prostaglandin I2, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Prostaglandin I2 industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Prostaglandin I2 in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Prostaglandin I2 introduction, etc. Prostaglandin I2 Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Prostaglandin I2 market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices